Physician profile
Hannah Leonard
NPI 1154871887
$6,383.68
in general payments reported to CMS, 2019-2025
28 companies · $2,081 in 2025
The $2,081 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $909 · 2022: $750 · 2023: $1,252 · 2024: $1,392 · 2025: $2,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,645 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,645.43 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,257.84 | 2021-2025 | |
| Genzyme Corporation | $804.99 | 2021-2025 | |
| Janssen Biotech, INC. | $749.66 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $521.94 | 2023-2025 | Sotyktu |
| Hill Dermaceuticals, INC. | $330.39 | 2025 | Tolak |
| Novartis Pharmaceuticals Corporation | $305.86 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $290.07 | 2021-2025 | Dupixent |
| Incyte Corporation | $248.50 | 2021-2025 | Opzelura |
| Pfizer INC. | $232.91 | 2021-2025 | |
| Ucb, INC. | $230.82 | 2025 | Bimzelx |
| Esperion Therapeutics, INC. | $186.25 | 2021 | |
| Amgen INC. | $178.08 | 2021-2023 | Otezla |
| Leo Pharma INC. | $173.29 | 2023-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $155.44 | 2021-2025 | Ilumya |
| Genentech USA, INC. | $118.79 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $110.71 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $105.53 | 2023-2024 | Zoryve |
| Journey Medical Corporation | $73.91 | 2022-2024 | |
| Galderma Laboratories, L.P. | $66.38 | 2021-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.40 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $34.64 | 2023 | Vtama |
| Botanix Sb INC | $32.26 | 2025 | Sofdra |
| Lnhc, INC | $30.17 | 2025 | Zelsuvmi |
| Mayne Pharma Commercial LLC | $28.85 | 2025 | |
| Organon LLC | $27.07 | 2024 | |
| Sandoz INC. | $19.88 | 2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $18.17 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.88 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Leonard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.